ESG Report 2019

23 Insulin Degludec Injection is a long-acting the original ground medicine, constantly insulin analogue with a similar acting optimized and improved it, and finally mechanism to insulin, producing the same established its preparation process and pharmacodynamic effects as human insulin, injection prescription process, which was and is incorporated in the National Drug approved by the National Medical Products Catalog for Basic Medical Insurance, Work- Administration for clinical trials in the Year. Related Injury Insurance, and Maternity The research and development and Insurance (2019 Edition). At present, this exploration of the Group's Degludec Insulin product has not been listed on any domestic Injection will effectively fill the vacancy of the enterprises. During the development process domestic new generation of basic insulin of Insulin Degludec, the Group insisted that products. the product quality has to be consistent with DIABETES DRUG RESEARCH AND DEVELOPMENT ACHIEVEMENTS VETERINARY MEDICINE RESEARCH AND DEVELOPMENT ACHIEVEMENTS During the Year, the new veterinary With a professional research and development p h a r ma c e u t i c a l " Amo x i c i l l i n S o d i um team, strong technical skills, abundant Clavulanate Potassium for Injection" resource investment, continuous innovation lyophilized powder independently developed capabilities and scientific enterprise by The United Animal Healthcare passed the management, The United Animal Healthcare registration approval of the new veterinary has continued to develop and innovate on the pharmaceutical of the Ministry of Agriculture application of veterinary pharmaceuticals, and and Rural Affairs of China, obtained the has reached a high level in transforming certificate in new veterinary drug, and was science and technological achievements. The approved for listing. The drug can be widely United Animal Healthcare was awarded the used to treat infections caused by Gram- "High-tech Enterprise Certificate" in the Year. negative and positive bacteria, can solve the Currently, in the aspect of veterinary drug resistance and residual problems of medicines research and development, it has related drugs in the market, bring technical obtained two second-class new veterinary innovation, and better achieve the effect of drug certificates, three patents, and multiple rapid treatment of livestock under African new national veterinary drug approvals and swine fever conditions. clinical trials in veterinary pharmaceutical research and development. Environmental, Social and Governance Report 2019 The United Laboratories International Holdings Limited